Ibutigen 140 mg
- Generic
- Ibrutinib
- Manufacturer
- General Pharmaceuticals Ltd.
- Drug class
- Targeted Cancer Therapy
Price
৳600 per unit
Packs & prices
- Pack of 120৳72,000
This is information only. Do not start, stop or switch medicines without a doctor's advice.
Warnings
Contraindications
Side effects
Pregnancy & lactation
Lactation: There is no information regarding the presence of Ibrutinib or its metabolites in human milk, the effects on the breast fed infant, or the effects on milk production.
Drug interactions
CYP3A Inducers: Co-administration with strong CYP3A inducers should be avoided
More information
Indications
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion Ibrutinib is indicated for the treatment of patients with chronic lymphocytic leukemia.
Waldenstrom Macroglobulinemia (WM): Ibrutinib is indicated for the treatment of patients with Waldenstrom Macroglobulinemia (WM).
Marginal Zone Lymphoma: Ibrutinib is indicated for the reatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD 20-based therapy.
Dosage
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia (WM): The recommended dose of Ibrutinib for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity. The recommended dose of Ibrutinib for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.
Administration
Swallow the capsules whole with water. Do not open, break, or chew the capsules.
Use in children
Geriatric Use: Of the 905 patients in clinical studies of Ibrutinib, 62% were ≥ 65 years of age, while 21% were ≥75 years of age. No overall differences in effectiveness were observed between younger and older patients. Anemia (all grades) and Grade 3 or higher pneumonia occurred more frequently among older patients treated with Ibrutinib.
Hepatic Impairment: Ibrutinib is metabolized in the liver. In a hepatic impairment study, data showed an increase in Ibrutinib exposure. The safety of Ibrutinib has not been evaluated in cancer patients with mild to severe hepatic impairment by Child-Pugh criteria. Monitor patients for signs of Ibrutinib toxicity and follow dose modification guidance as needed. It is not recommended to administer Ibrutinib to patients with moderate or severe hepatic impairment.
Overdose
Pharmacology
Therapeutic class
Storage
Source: medex.com.bd · Prescribing information (PDF)
Cheaper alternatives
Same generic, strength and form — sorted by price
ButinibCheapest
Drug International Ltd.
৳500
৳100 less (17%)
Ibrucent
Incepta Pharmaceuticals Ltd.
৳500
৳100 less (17%)
Ibrunib
Jenphar Bangladesh Ltd.
৳550
৳50 less (8%)
Ibrutab
Eskayef Pharmaceuticals Ltd.
৳600
Same price
Notafol
Genvio Pharma Ltd.
৳750
৳150 more
Ibruxen
Everest Pharmaceuticals Ltd.
৳1,320
৳720 more
Ibrutix
Beacon Pharmaceuticals Ltd.
৳1,326
৳726 more